Clinical Trials
27 trialsSTIM 2
University Hospital, Bordeaux
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Fred Hutchinson Cancer Center
What is the Impact of TKI on Thyroid Function in CML Patients?
Assiut University
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia (CML) Real-Life Database
University Hospital, Clermont-Ferrand
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
European Institute of Oncology
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
University of Seville
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
University of British Columbia
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
University of British Columbia
SIMPly-CARE
Rigshospitalet, Denmark
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
First Affiliated Hospital of Zhejiang University
The Association of Microbiota Composition With cGVHD After Allo-HSCT
First Affiliated Hospital of Zhejiang University
TFR_china
Shenzhen Second People's Hospital
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
University of Milano Bicocca
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Fundación Teófilo Hernando, Spain
ProT4
University College, London
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
WIN
University Hospital Southampton NHS Foundation Trust
A-STIM
Versailles Hospital
SPIRIT2
Newcastle University
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
University of California, San Diego
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
University of Pittsburgh
Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease
Ohio State University Comprehensive Cancer Center
Rituximab for Prevention of Chronic GVHD
Dana-Farber Cancer Institute
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
STIM
University Hospital, Bordeaux
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Ann & Robert H Lurie Children's Hospital of Chicago